EP1064022A4 - Hla-bindeproteine und deren verwendung - Google Patents

Hla-bindeproteine und deren verwendung

Info

Publication number
EP1064022A4
EP1064022A4 EP98910404A EP98910404A EP1064022A4 EP 1064022 A4 EP1064022 A4 EP 1064022A4 EP 98910404 A EP98910404 A EP 98910404A EP 98910404 A EP98910404 A EP 98910404A EP 1064022 A4 EP1064022 A4 EP 1064022A4
Authority
EP
European Patent Office
Prior art keywords
hla
binding peptides
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910404A
Other languages
English (en)
French (fr)
Other versions
EP1064022A1 (de
Inventor
Alessandro Sette
Ralph T Kubo
John Sidney
Esteban Celis
Howard M Grey
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1064022A1 publication Critical patent/EP1064022A1/de
Publication of EP1064022A4 publication Critical patent/EP1064022A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98910404A 1998-03-13 1998-03-13 Hla-bindeproteine und deren verwendung Withdrawn EP1064022A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/005039 WO1999045954A1 (en) 1998-03-13 1998-03-13 Hla-binding peptides and their uses

Publications (2)

Publication Number Publication Date
EP1064022A1 EP1064022A1 (de) 2001-01-03
EP1064022A4 true EP1064022A4 (de) 2004-09-29

Family

ID=22266589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910404A Withdrawn EP1064022A4 (de) 1998-03-13 1998-03-13 Hla-bindeproteine und deren verwendung

Country Status (5)

Country Link
EP (1) EP1064022A4 (de)
JP (1) JP2002507397A (de)
AU (1) AU6465598A (de)
CA (1) CA2323632A1 (de)
WO (1) WO1999045954A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
EP1117679B9 (de) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
NZ512052A (en) * 1998-12-01 2003-10-31 Sumitomo Pharma Novel tumor antigen protein art-1 and tumor antigen peptide thereof
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
AU1440601A (en) * 1999-10-29 2001-05-14 Argonex Pharmaceuticals, Inc. Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
ATE445643T1 (de) * 1999-11-18 2009-10-15 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1237564A4 (de) * 1999-12-10 2005-05-04 Epimmune Inc Induktion zellulärer immunantworten gegen p53 mittels peptid und nukleinsäure-verbindungen
EP1235841A4 (de) * 1999-12-10 2006-04-12 Epimmune Inc Induzierung von zellulärer immunantwort auf mage2/3 mit hilfe von peptid- und nukleinsäurezubereitungen
JP2003521245A (ja) * 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
AU2001295008A1 (en) * 2000-08-14 2002-02-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies
WO2002020053A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
AU2002239410B2 (en) 2000-10-31 2008-05-01 Eisai Inc. CYP1B1 nucleic acids and methods of use
EP1490396A4 (de) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe
CN100589845C (zh) * 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
EP1752160A3 (de) * 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2002080848A2 (en) 2001-04-09 2002-10-17 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
WO2002094994A2 (en) 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
CA2449715A1 (en) * 2001-06-05 2002-12-12 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea Peptides for chlamydophila pneumoniae vaccine and diagnosis
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2003063770A2 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
US20060018915A1 (en) * 2002-04-05 2006-01-26 Glenn Ishioka Heteroclitic analogs and related methods
DK1587837T3 (da) 2003-01-28 2012-09-24 Proscan Rx Pharma Inc Epitopsekvenser til diagnose og behandling af prostatacancer
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
EP2481422A3 (de) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex-Impfstoffe
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
CA2539789A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Peptide originating in hepatitis c virus
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2005103679A2 (en) 2004-04-21 2005-11-03 Algonomics Nv Method for affinity scoring of peptide/protein complexes
US20080249283A1 (en) * 2004-04-30 2008-10-09 Tomoya Miyakawa Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences
WO2006035681A1 (ja) * 2004-09-27 2006-04-06 National University Corporation Tokyo Medical And Dental University ＨＬＡ－Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ
US20080306243A1 (en) * 2005-09-07 2008-12-11 Nec Corporation Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide
EP2016095A2 (de) 2006-04-13 2009-01-21 Peptimmune, Inc. Verfahren zur entwicklung und synthese von zusammensetzungen mit einem polymer mit gerichteter sequenz über die gerichtete expansion der epitoppermeabilität
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
JP5573679B2 (ja) 2008-01-18 2014-08-20 アエラス グローバル ティービー ワクチン ファウンデーション マラリアワクチン組成物および細胞媒介免疫性を惹起する成分
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
CA2775720A1 (en) * 2009-09-30 2011-04-07 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses
US20130183376A1 (en) * 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
CN102286075A (zh) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 乙肝病毒表面抗原的免疫显性hla-a*1101限制性ctl表位及其应用
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
KR102047323B1 (ko) * 2012-01-20 2019-11-21 페르난도 토메 크뤠츠 자가 암 세포 백신
JP5999703B2 (ja) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
AU2016221777A1 (en) * 2015-02-18 2017-08-31 F. Hoffmann-La Roche Ag Immunoconjugates for specific induction of T cell cytotoxicity against a target cell
CN105037559B (zh) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
IL309003A (en) 2015-08-28 2024-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides and supports for use in immunotherapy in different types of cancer
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
MX2019007924A (es) 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
KR20200047660A (ko) * 2017-09-01 2020-05-07 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드
EP3545967A1 (de) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Krebsimmunisierungsplattform
CN113939527A (zh) * 2019-01-11 2022-01-14 新加坡科技研究局 Hla-a*11:01限制性乙型肝炎病毒(hbv)肽用于鉴别hbv特异性cd8+ t细胞的用途
AU2020231928A1 (en) * 2019-03-04 2021-10-07 University Health Network T cell receptors and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1998032456A1 (en) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1998032456A1 (en) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTUVIA YAEL ET AL: "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets", HUMAN IMMUNOLOGY, vol. 58, no. 1, November 1997 (1997-11-01), pages 1 - 11, XP002279422, ISSN: 0198-8859 *
GREY H M ET AL: "CLASS I MHC-PEPTIDE INTERACTIONS: STRUCTURAL REQUIREMENTS AND FUNCTIONAL IMPLICATIONS", CANCER SURVEYS, OXFORD, GB, vol. 22, 1995, pages 37 - 49, XP008024840 *
PARTIDOS C D ET AL: "Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides", IMMUNOLOGY, vol. 87, no. 2, 1996, pages 179 - 185, XP002279421, ISSN: 0019-2805 *
See also references of WO9945954A1 *

Also Published As

Publication number Publication date
WO1999045954A1 (en) 1999-09-16
CA2323632A1 (en) 1999-09-16
AU6465598A (en) 1999-09-27
EP1064022A1 (de) 2001-01-03
JP2002507397A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
EP1064022A4 (de) Hla-bindeproteine und deren verwendung
HUP0102535A3 (en) Cd19xcd3 specific polypeptides and uses thereof
PL344341A1 (en) Peptides
PL346346A1 (en) Cyclic prosaposin-derived peptides and uses thereof
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
EP1021185A4 (de) Dihydropyrimidine und ihre verwendungen.
EP0894807A4 (de) GPIb-Lipidcomplex und dessen Anwendungen
IL131368A0 (en) Antipathogenic synthetic peptides and compositions comprising them
GB9806806D0 (en) Peptides and uses thereof
EP1056465A4 (de) Antimikrobielle peptide und abgeleitete metapeptide
ZA97283B (en) Isolated tyrosinase derived peptides and uses thereof
EP0750679A4 (de) Isolierte von tyrosinase abgeleitete peptide und ihre verwendung
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB9825854D0 (en) Peptide
GB9718110D0 (en) Peptides
HK1046925A1 (zh) Mage-a12抗原肽及其用途
GB9918155D0 (en) Proteins and peptides
GB9714276D0 (en) Peptides and related compounds
GB9812675D0 (en) Peptides
GB9700154D0 (en) Peptides
EP1080185A4 (de) Basische proteinpeptide des myelin sowie verwendung derselben.
IL145711A0 (en) Thrombospondin-2 and uses thereof
EP0998578A4 (de) Sel-10 und dessen verwendungen
EP0996457A4 (de) Fsh freisetzende peptide
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/82 B

Ipc: 7C 07K 14/02 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/29 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040813

17Q First examination report despatched

Effective date: 20070820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401